Bicycle Therapeutics reported significant advancements in its business and pipeline, including updated data on clinical-stage molecules and first human imaging data for its radiopharmaceuticals. The company highlights the capabilities of its Bicycle technology platform and anticipates further updates later this year.
Company Information
Company
Bicycle Therapeutics
About
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Bicycle Therapeutics ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
